(Reuters) — AcelRx Pharmaceuticals (NSDQ:ACRX) said the FDA wants an additional study on its Zalviso drug-device combination, which the safety watchdog already rejected once last year.
Pain Management
Nevro surges on Senza approvable letter from FDA
Stimwave Technologies launches new chronic pain trial for mini neurostim device
Stimwave Technologies said it’s launching a new clinical trial for its miniature, wireless neuromodulation anti-pain device for treating chronic, non-specific-origin lower back pain.
Spinal Modulation closes enrollment in Axium chronic pain study
Spinal Modulation said it completed enrollment in a U.S. pivotal study of its Axium neurotransmitter system for the treatment of chronic pain.
Nevro boosts IPO to $126m
Nevro Corp. today raised the stakes on its forthcoming initial public offering, saying it will offer half a million more shares at a dollar over the high end of its prior range.
Funding: InSightec raises $12.5M from Chinese backers
Israeli device maker InSightec added $12.5 million to its coffers thanks to the support of Chinese backers, the firm’s parent company announced.
Appeals court upholds dismissal of pain pump suit against Stryker, Orthofix, others
St. Jude closes $200M NeuroTherm buy
Medtech titan St. Jude Medical (NYSE:STJ) officially entered the spinal pain market this week, announcing the close of its $200 million cash acquisition of NeuroTherm.
St. Jude drops $200M on NeuroTherm for spinal pain device
Minnesota-based medtech giant St. Jude Medical (NYSE:STJ) is broaching new ground in the spinal pain market with the $200 million acquisition of NeuroTherm, maker of radiofrequency ablation therapies.